Access the full text.
Sign up today, get DeepDyve free for 14 days.
R. Rubens (1992)
Management of early breast cancer.British Medical Journal, 304
Makris Makris, Powles Powles, Dowsett Dowsett (1995)
Changes in proliferation in primary breast cancers during chemoendocrine therapyEuropean Journal of Cancer, 31A
G. Hortobagyi, F. Ames, A. Buzdar, S. Kau, M. Mcneese, D. Paulus, V. Hug, F. Holmes, M. Romsdahl, G. Fraschini, C. McBride, R. Martin, E. Montague (1988)
Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapyCancer, 62
G. Draper (1995)
Childhood cancer: trends in incidence, survival and mortality.European journal of cancer, 31A 5
U. Veronesi, A. Banfi, B. Salvadori, A. Luini, R. Saccozzi, R. Zucali, E. Marubini, M. Vecchio, P. Boracchi, Silvana Marchini, M. Merson, V. Sacchini, G. Riboldi, G. Santoro (1990)
Breast conservation is the treatment of choice in small breast cancer: long-term results of a randomized trial.European journal of cancer, 26 6
B. Mason, I. Holdaway, P. Mullins, L. Yee, R. Kay (1983)
Progesterone and estrogen receptors as prognostic variables in breast cancer.Cancer research, 43 6
Ellis Ellis, Smith Smith, Salter Salter (1996)
Pre‐operative/Neoadjuvant chemotherapy for early breast cancer induces apoptosisProceedings of the Annual Meeting of the American Society of Clinical Oncology, 15
H. Mouridsen, C. Rose, M. Nooy, A. Oosterom (1983)
Mitoxantrone as first line cytotoxic therapy in advanced breast cancer: preliminary results of a phase II study.Cancer treatment reviews, 10 Suppl B
Jones Jones, Smith Smith, O'Brien O'Brien (1994)
Phase II study of continuous infusional 5FU with epirubicin and cisplatin (infusional ECF) in patients with metastatic and locally advanced breast cancer: an active new regimenJournal of Clinical Oncology, 12
Early Group (1992)
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 womenThe Lancet, 339
M. Cornbleet, R. Stuart-Harris, I. Smith, R. Coleman, R. Rubens, M. Mcdonald, H. Mouridsen, H. Rainer, A. Oosterom, J. Smyth (1984)
Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients.European journal of cancer & clinical oncology, 20 9
A. Jones, I. Smith, M. O'Brien, D. Talbot, G. Walsh, F. Ramage, H. Robertshaw, S. Ashley (1994)
Phase II study of continuous infusion fluorouracil with epirubicin and cisplatin in patients with metastatic and locally advanced breast cancer: an active new regimen.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 12 6
Goldie Goldie, Coldman Coldman (1979)
A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rateCancer Treatment Reviews, 63
T. Powles, Alys Jones, I. Judson, J. Hardy, S. Ashley (1991)
A randomised trial comparing combination chemotherapy using mitomycin C, mitozantrone and methotrexate (3M) with vincristine, anthracycline and cyclophosphamide (VAC) in advanced breast cancer.British Journal of Cancer, 64
L. Mauriac, M. Durand, A. Avril, J. Dilhuydy (1991)
Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumors larger than 3 cm. Results of a randomized trial in a single centre.Annals of oncology : official journal of the European Society for Medical Oncology, 2 5
S. Scholl, A. Fourquet, B. Asselain, J. Pierga, J. Vilcoq, J. Durand, T. Dorval, T. Palangié, M. Jouve, P. Beuzeboc, E. Garcio-Giralt, R. Salmon, A. Rochefordière, F. Campana, P. Pouillart (1994)
Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6.European journal of cancer, 30A 5
T. Powles, T. Hickish, A. Makris, S. Ashley, M. O'Brien, V. Tidy, S. Casey, A. Nash, N. Sacks, D. Cosgrove (1995)
Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 13 3
MD' JACQUILLAT, MD Weil, MD Baillet, MD Borel, MD Auclerc, MD Maublanc, MD Housset, PhM Forget, MD Thill, MD Soubrane, MD Khayat (1990)
Results of neoadjuvant chemotherapy and radiation therapy in the breast‐conserving treatment of 250 patients with all stages of infiltrative breast cancerCancer, 66
Makris Makris, Powles Powles, Ashley Ashley (1996)
A randomized trial of neoadjuvant chemoendocrine therapy in operable breast cancerProceedings of the Annual Meeting of the American Society of Clinical Oncology, 15
G. Bonadonna, Umberto Veronesi, C. Brambilla, L. Ferrari, A. Luini, M. Greco, C. Bartoli, Gianfranco Yoldi, R. Zucali, F. Rilke, S. Andreola, R. Silvestrini, G. Fronzo, P. Valagussa (1990)
Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more.Journal of the National Cancer Institute, 82 19
B. Fisher, C. Redmond, R. Poisson, R. Margolese, N. Wolmark, L. Wickerham, Edwin Fisher, M. Deutsch, R. Caplan, Y. Pilch, A. Glass, H. Shibata, H. Lerner, J. Terz, L. Sidorovich (1989)
Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer.The New England journal of medicine, 320 13
A. Montes, T. Powles, M. O'Brien, S. Ashley, J. Luckit, J. Treleaven (1993)
A toxic interaction between mitomycin C and tamoxifen causing the haemolytic uraemic syndrome.European journal of cancer, 29A 13
(1992)
Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group.Lancet, 339 8785
Makris Makris, Powles Powles (1995)
Primary medical therapy in the treatment of operable breast cancerCancer Topics, 10
V. Hug, G. Hortobagyi, B. Drewinko, M. Finders (1985)
Tamoxifen-citrate counteracts the antitumor effects of cytotoxic drugs in vitro.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 3 12
H. Muss, A. Thor, D. Berry, T. Kute, E. Liu, F. Koerner, C. Cirrincione, D. Budman, W. Wood, M. Barcos, I. Henderson (1994)
c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.The New England journal of medicine, 330 18
B. Fisher, E. Saffer, C. Rudock, J. Coyle, N. Gunduz (1989)
Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice.Cancer research, 49 8
Fisher Fisher, Brown Brown, Mamounas Mamounas (1997)
Effect of preoperative therapy for primary breast cancer (BC) on localregional disease, disease‐free survival (DFS) and survival (S): results from NSABP B‐18Proceedings of the Annual Meeting of the American Society of Clinical Oncology, 16
C. Osborne, L. Kitten, C. Arteaga (1989)
Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 7 6
P. Plowman, W. Allum, T. Powles, I. Smith, B. Zumoff, A. Rostom, A. Gershuny, H. Kaplan, H. Goodare (1992)
Adjuvant treatment in breast cancerThe Lancet, 339
S. Scholl, J. Pierga, B. Asselain, P. Beuzeboc, T. Dorval, E. Garcia-Giralt, M. Jouve, T. Palangié, Y. Remvikos, J. Durand, A. Fourquet, P. Pouillart (1995)
Breast tumour response to primary chemotherapy predicts local and distant control as well as survival.European journal of cancer, 31A 12
The use of neoadjuvant chemotherapy in primary breast cancer is based on sound theoretical, experimental and clinical principles. Higher objective response rates have been seen in patients with locally advanced breast carcinoma. Furthermore, when used in patients with operable breast carcinomas, sufficient downstaging has been achieved to allow for breast conservation surgery in patients who would otherwise require a mastectomy. This has been achieved without an increase in local recurrence. The anthracenedione mitoxantrone was used as part of the 3M/2M regimen in the neoadjuvant trial at the Royal Marsden Hospital, which was the first to establish within the setting of a clinical trial, the reduction in mastectomy requirements. This regimen combined high objective response rate with low symptomatic toxicity. An important benefit of neoadjuvant therapy is the opportunity to study in vivo the effects of treatment in primary breast carcinomas. The use of the primary tumour as a marker of response prior to surgery may, in the future, allow for the optimization of therapy for individual patients.
European Journal of Cancer Care – Wiley
Published: Jun 1, 1997
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.